^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IOS-1002

    i
    Other names: IOS-1002, iosH2, ios H2, ios-H2
    Associations

    News

    Trials
    Company:
    ImmunOs Therap
    Drug class:
    ILT-2 inhibitor, ILT-4 inhibitor, KIR3DL1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. (PubMed, Cancer Discov)
    The ERAP1 inhibitor GRWD5769 combined with cemiplimab, a PD-1 inhibitor, has shown preliminary promise in overcoming resistance to PD-(L)1 blockade by targeting antigen processing. Another resistance-mitigating strategy is potentially IOS-1002, an antagonist of two immunosuppressive receptors, LILRB1/2 and KIR3DL1, combined with anti-PD-1 pembrolizumab. As well, an update on the recently published DART (NCI/SWOG S1609) study indicates that the classic combination of ipilimumab with nivolumab may benefit even more rare cancers, including gestational trophoblastic neoplasia.
    Journal
    |
    KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc) • GRWD5769 • IOS-1002
    2ms
    KEYNOTE-F49: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, ImmunOs Therapeutics AG | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: May 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
    |
    Keytruda (pembrolizumab) • IOS-1002
    over1year
    KEYNOTE-F49: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=140, Recruiting, ImmunOs Therapeutics AG | Trial primary completion date: May 2024 --> May 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    Keytruda (pembrolizumab) • IOS-1002
    almost2years
    IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity. (PubMed, Cancers (Basel))
    Lastly, IOS-1002 demonstrates efficacy in an ex vivo patient-derived tumor sample tumoroid model. IOS-1002 is a first-in-class multi-target and multi-functional human-derived HLA molecule that activates anti-tumor immunity and is currently under clinical evaluation.
    Journal
    |
    B2M (Beta-2-microglobulin) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)
    |
    IOS-1002
    over2years
    KEYNOTE-F49: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=140, Recruiting, ImmunOs Therapeutics AG | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    Keytruda (pembrolizumab) • IOS-1002
    almost3years
    A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors (ESMO 2023)
    Dose Expansion (B): Following the toxicity and activity profile observed in part A, a tumor-specific cohort expansion study in up to 6 potential disease entities with 20 patients per cohort will be initiated, 3 as IOS-1002 monotherapy and 3 as IOS-1002 + PD-1 combination. Depending on the disease entity and line of treatment, the PD-1 cohort will include PD-1 naïve, pre-exposed and refractory patients, respectively.
    Clinical • P1 data • Combination therapy • Metastases
    |
    B2M (Beta-2-microglobulin) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)
    |
    IOS-1002
    3years
    A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=140, Recruiting, ImmunOs Therapeutics AG | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    IOS-1002
    over3years
    A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=140, Not yet recruiting, ImmunOs Therapeutics AG
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    IOS-1002